Navigation Links
MAP Pharmaceuticals Announces Completion of Enrollment in Phase 3 Clinical Trial of MAP0004 in Patients with Migraine
Date:1/26/2009

MOUNTAIN VIEW, Calif., Jan. 26 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it has completed patient enrollment in the efficacy portion of its initial Phase 3 clinical trial evaluating MAP0004, the company's novel, orally inhaled product candidate for the acute treatment of migraine.

"In our Phase 2 clinical trial, MAP0004 demonstrated the potential to be both fast acting and long-lasting, providing pain relief in as fast as ten minutes with relief lasting for 24 and 48 hours, so we believe that MAP0004 has the potential to be a first-line therapy for migraine patients. We would like to thank our investigators as well as their patients for their strong interest and support for studying the potential benefits of MAP0004," said Timothy S. Nelson, President and Chief Executive Officer of MAP Pharmaceuticals. "We look forward to announcing clinical data from the efficacy portion of the trial in the first half of this year."

The Phase 3 multi-center, randomized, double-blind, placebo-controlled trial in approximately 850 migraine sufferers is evaluating the safety and efficacy of MAP0004 as a potential acute treatment for migraine. The primary efficacy endpoints are pain relief and freedom from nausea, photophobia and phonophobia as measured at two hours after dosing. The study is also evaluating earliest onset of pain relief, pain relief at 10 minutes, and sustained pain relief and freedom at 24 and 48 hours. Patients enrolled in the trial are being evaluated for the treatment of a single migraine and may continue in a long-term safety arm of the trial, enrollment in which is ongoing. MAP Pharmaceuticals is conducting this first Phase 3 trial pursuant to a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration.

MAP0004 is a novel, o
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Axikin Pharmaceuticals Spins out of Actimis
2. BioMed Realty Trust Extends Leases With Vertex Pharmaceuticals Through 2015
3. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
4. Cumberland Pharmaceuticals Appoints Lee Product Director
5. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
6. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
7. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
8. Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities
9. Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin
10. MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs
11. Endo Pharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... COLLEGE STATION, Texas , July 28, 2014   The ... be a 177-key, 4-star boutique hotel in the heart of The ... Texas.  Photo - http://photos.prnewswire.com/prnh/20140725/130455 ... hotel within ATLAS , The ... standard rooms and suites, a sleek restaurant and bar, a wellness ...
(Date:7/25/2014)... NY (PRWEB) July 26, 2014 ... Review, H2, 2014" provides data on the Ischemic ... report provides elemental information and data relating to ... Stroke. , View full global Ischemic Stroke Research ... includes an overview of the trial numbers and ...
(Date:7/25/2014)... , July 25, 2014 Research ... "Global Metabolomics Market 2014-2018" report to ... Metabolomics or Metabonomics is the ... has become a new experimental technique that is ... environmental sciences. Metabolites are small molecules that are ...
(Date:7/25/2014)... 2014 Lawrence Livermore scientists Charles Westbrook ... list of " The World's Most Influential Scientific Minds ... 3,000 researchers who were identified by analyzing citation data ... published the highest-impact work (2002-2012 and 2012-2013). The two ... combustion modeling . , "This recognition is a great ...
Breaking Biology Technology:Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 2Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 3Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 4Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon 2Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4
... To Receive $2 Million Milestone Payment, CARLSBAD, ... ISIS ) announced today that Bristol-Myers,Squibb Company ... from the companies,collaboration as a development candidate. As ... payment. The two companies have an ongoing,collaboration to ...
... Now Providing ... Medicaid Coverage for Trofile, SOUTH SAN FRANCISCO, ... ) today announced that New York,Medicaid has established coverage and ... candidacy for Pfizer,s new,HIV anti-viral medication Selzentry(TM) (maraviroc)., Initiated ...
... 7, 2008 Martek,Biosciences Corporation announced today that ... Maryland has entered a Final Judgment and Order,of ... action,brought on behalf of certain purchasers of Martek ... federal securities laws and arose out of,allegations, among ...
Cached Biology Technology:BRISTOL-MYERS SQUIBB SELECTS ISIS DRUG TARGETING PCSK9 AS DEVELOPMENT CANDIDATE FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE 2BRISTOL-MYERS SQUIBB SELECTS ISIS DRUG TARGETING PCSK9 AS DEVELOPMENT CANDIDATE FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE 3BRISTOL-MYERS SQUIBB SELECTS ISIS DRUG TARGETING PCSK9 AS DEVELOPMENT CANDIDATE FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE 4New York Medicaid Program Establishes Coverage for Trofile(TM) 2New York Medicaid Program Establishes Coverage for Trofile(TM) 3New York Medicaid Program Establishes Coverage for Trofile(TM) 4Martek Announces Final Judgment and Order of Dismissal in Class Action 2
(Date:7/27/2014)... discovered a new species of mayfly in the southern Western ... In fact, this is the first time that any mayfly ... in peninsular India. , The new species, called Labiobaetis ... for his substantial contribution to the understanding of the Ephemeroptera ... a study that describes the new mayfly in the ...
(Date:7/27/2014)... In an age of "big data," a single computer ... tasks must instead be distributed across a cluster of ... how Facebook and Google mine your web history to ... Netflix recommend your next favorite book or movie. But ... , New technologies for monitoring brain activity are generating ...
(Date:7/25/2014)... false-color image from the Terra satellite show the different areas ... in Eastern Russia. The burn scars show up as ... wildfires have broken across the remote parts of Eastern Russia ... from the MODIS instrument, it is still possible to ... recent image features noted below show the devastating number of ...
Breaking Biology News(10 mins):New tools help neuroscientists analyze 'big data' 2New tools help neuroscientists analyze 'big data' 3New tools help neuroscientists analyze 'big data' 4New tools help neuroscientists analyze 'big data' 5
... microbes in the Earth,s oceans consume 90 percent of ... in ice preventing large amounts of methane from ... two microbes that accomplish this feat do not simply ... sulfur compound instead. "The dominant role anaerobic oxidation ...
... 16, 2008) -- Two major federal grants have been awarded ... New York City. Dr. Kenneth W. Griffin is ... the National Institute on Drug Abuse (NIDA) for research into ... delivered to urban minority youth attending New York City middle ...
... medications can delay the onset of Alzheimer,s disease, but none ... makes early detection the key to Alzheimers patients maintaining a ... Now, a new device developed by the Georgia Institute ... a brief, inexpensive test that could be administered as part ...
Cached Biology News:Paired microbes eliminate methane using sulfur pathway 22 federal public health grants awarded to Weill Cornell Medical College 2Portable device quickly detects early Alzheimer's 2Portable device quickly detects early Alzheimer's 3
Mouse monoclonal antibody to QARS - glutaminyl-tRNA synthetase...
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
Heavy-duty rim. Especially recommended as a titration flask. Corning5100. capacity 250 mL Special grade: student grade...
... CLS number is a ... to easily match Cornings ... no availability yet, please ... Sigma-Aldrich number (Z71,448-8) or ...
Biology Products: